Shilpa Medicare updates on launch of Pemetrexed Injection, 100mg/10 ml, 500 mg/50 ml, 1000 mg/100 ml

Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU® (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market. The product has already been granted permanent J-code (J9324) by U.S. Centers for Medicare & Medicaid Services (CMS).

Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents. It is also indicated in the treatment of mesothelioma in combination with cisplatin. PEMRYDI RTU® is a novel ready-to-use injection which eliminates the need for refrigeration or reconstitution and dilution for administration to the patient. This offers hospitals and oncology clinics a new, value-added presentation that should improve pharmacy efficiency by eliminating preparation steps and freeing up refrigerator space. Currently product is available in two vial sizes: 100mg/10mL and 500 mg/50mL, and we intend to introduce 1000mg/100mL soon in the market.

According to IQVIA®, U.S. annual sales for pemetrexed for the 12 months ended February 2024 were $287 million.

Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the Oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 534.55 as compared to the previous close of Rs. 526.00. The total number of shares traded during the day was 63871 in over 2828 trades.

The stock hit an intraday high of Rs. 541.00 and intraday low of 515.00. The net turnover during the day was Rs. 33785764.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 AmnealPharmaceuticals PEMRYDIRTU USMarket